ATE533488T1 - Verfahren und formulierungen zur modulierung von lyn-kinaseaktivität und behandlung assoziierter erkrankungen - Google Patents
Verfahren und formulierungen zur modulierung von lyn-kinaseaktivität und behandlung assoziierter erkrankungenInfo
- Publication number
- ATE533488T1 ATE533488T1 AT06813647T AT06813647T ATE533488T1 AT E533488 T1 ATE533488 T1 AT E533488T1 AT 06813647 T AT06813647 T AT 06813647T AT 06813647 T AT06813647 T AT 06813647T AT E533488 T1 ATE533488 T1 AT E533488T1
- Authority
- AT
- Austria
- Prior art keywords
- formulations
- kinase activity
- disorder
- compounds
- methods
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010033645 Pancreatitis Diseases 0.000 abstract 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 abstract 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 208000018914 glucose metabolism disease Diseases 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 208000013223 septicemia Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Otolaryngology (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70979805P | 2005-08-22 | 2005-08-22 | |
| US80853306P | 2006-05-26 | 2006-05-26 | |
| PCT/US2006/032788 WO2007024863A2 (en) | 2005-08-22 | 2006-08-22 | Methods and formulations for modulating lyn kinase activity and treating related disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE533488T1 true ATE533488T1 (de) | 2011-12-15 |
Family
ID=37635750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06813647T ATE533488T1 (de) | 2005-08-22 | 2006-08-22 | Verfahren und formulierungen zur modulierung von lyn-kinaseaktivität und behandlung assoziierter erkrankungen |
Country Status (11)
| Country | Link |
|---|---|
| US (8) | US7776870B2 (de) |
| EP (1) | EP1924262B1 (de) |
| JP (1) | JP5113752B2 (de) |
| KR (2) | KR101452518B1 (de) |
| AT (1) | ATE533488T1 (de) |
| AU (1) | AU2006283211B2 (de) |
| BR (1) | BRPI0615046C1 (de) |
| CA (1) | CA2620065C (de) |
| IL (1) | IL189603A0 (de) |
| NZ (1) | NZ565955A (de) |
| WO (1) | WO2007024863A2 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101452518B1 (ko) * | 2005-08-22 | 2014-10-21 | 멜리어 파마슈티칼스 아이, 인코포레이티드 | Ｌｙｎ 키나제 활성의 조절 및 관련된 장애의 치료를 위한방법 및 제제 |
| EP2120581A4 (de) * | 2007-02-20 | 2011-03-16 | Melior Pharmaceuticals I Inc | Verfahren zur identifikation von aktivatoren der lyn-linase |
| US20100160339A1 (en) * | 2007-05-21 | 2010-06-24 | Mayo Foundation For Medical Education And Research | Treating pancreatitis |
| EP2180894A4 (de) * | 2007-07-23 | 2012-08-29 | Melior Pharmaceuticals I Inc | Verfahren zur aktivierung von irs-1 und akt |
| US8552184B2 (en) * | 2008-07-03 | 2013-10-08 | Melior Pharmaceuticals I, Inc. | Compounds and methods for treating disorders related to glucose metabolism |
| WO2011150300A1 (en) * | 2010-05-28 | 2011-12-01 | Melior Pharmaceuticals I, Inc. | Prevention of pancreatic beta cell degeneration |
| SG11201403207WA (en) * | 2011-12-12 | 2014-09-26 | Melior Pharmaceuticals I Inc | Treatment of type i and type ii diabetes |
| WO2014100636A2 (en) * | 2012-12-20 | 2014-06-26 | The Trustees Of Columbia University In The City Of New York | Methods of treating atherosclerosis or myeloproliferative neoplasms by administering a lyn kinase activator |
| JO3546B1 (ar) | 2015-01-09 | 2020-07-05 | Kyowa Kirin Co Ltd | طريقة لإنتاج مشتق ثيازول |
| EP3609500B1 (de) | 2017-04-10 | 2024-11-13 | Melior Pharmaceuticals I, Inc. | Behandlung von adipozyten |
| CA3088178A1 (en) | 2018-02-21 | 2019-08-29 | Melior Pharmaceuticals I, Inc. | Treatment of liver diseases |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3174901A (en) * | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
| BE790125A (fr) * | 1971-10-29 | 1973-04-16 | Pfizer | Nouvelles pyrimidinones et nouvelles hydroxypyrimidines |
| US3922345A (en) * | 1971-10-29 | 1975-11-25 | Pfizer | Pyrimidinones and hydroxy pyrimidines |
| US4080454A (en) | 1976-07-16 | 1978-03-21 | Pfizer Inc. | 5-M-Tolyloxyuracil, anti-ulcer agent |
| US4612376A (en) | 1983-03-25 | 1986-09-16 | Fujisawa Pharmaceutical Co., Ltd. | Substituted-3,4-dihydro-4-(2,4,6-trimethoxyphenylimino)-2(1H)-pyrimidones useful as cardiotonic, antihypertensive, cerebrovascular vasodilator and anti-platelet agent |
| US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
| GB9214720D0 (en) | 1992-07-10 | 1992-08-19 | Wellcome Found | Enzyme inhibitors |
| SE9203753D0 (sv) | 1992-12-11 | 1992-12-11 | Kabi Pharmacia Ab | Expression system for producing apolipoprotein ai-m |
| US5476855A (en) | 1993-11-02 | 1995-12-19 | Mahmoud H. el Kouni | Enzyme inhibitors, their synthesis and methods for use |
| US6900304B2 (en) | 1996-01-31 | 2005-05-31 | The Regents Of The University Of California | Emission ratiometric indicators of phosphorylation |
| US20020019346A1 (en) | 1997-05-21 | 2002-02-14 | Children's Medical Center Corporation | Treatment of prostate cancer by inhibiting lyn tyrosine kinase |
| US6037323A (en) | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6004925A (en) | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
| US6410255B1 (en) | 1999-05-05 | 2002-06-25 | Aurora Biosciences Corporation | Optical probes and assays |
| US20010036479A1 (en) | 2000-01-14 | 2001-11-01 | Gillian Cave | Glyburide composition |
| GB0104422D0 (en) | 2001-02-22 | 2001-04-11 | Glaxo Group Ltd | Quinoline derivative |
| US20030198666A1 (en) | 2002-01-07 | 2003-10-23 | Richat Abbas | Oral insulin therapy |
| US7985422B2 (en) | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| US7232828B2 (en) | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
| US20050009817A1 (en) | 2003-04-30 | 2005-01-13 | Jennifer Savoy | Substituted heteroaryls |
| US20050208054A1 (en) | 2003-12-09 | 2005-09-22 | University Of Massachusetts | Methods of identifying insulin response modulators and uses therefor |
| EP1541694A1 (de) | 2003-12-12 | 2005-06-15 | Sirenade Pharmaceuticals AG | Verfahren zur Identifizierung, Auswahl und Charakterisierung von Substanzen welche die Aktivität von Kinasen der Src Familien modulieren |
| US20060035302A1 (en) | 2004-06-21 | 2006-02-16 | Applera Corporation | Kinase substrates with multiple phosphorylation sites |
| MX2007006230A (es) | 2004-11-30 | 2007-07-25 | Amgen Inc | Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer. |
| WO2007016975A1 (en) | 2005-07-29 | 2007-02-15 | F. Hoffmann-La Roche Ag | Kinase and phosphatase assays based on fret |
| US20070025953A1 (en) | 2005-07-27 | 2007-02-01 | Jones Michael R | Co-therapy for diabetic conditions |
| KR101452518B1 (ko) * | 2005-08-22 | 2014-10-21 | 멜리어 파마슈티칼스 아이, 인코포레이티드 | Ｌｙｎ 키나제 활성의 조절 및 관련된 장애의 치료를 위한방법 및 제제 |
| SI1924264T1 (sl) | 2005-09-01 | 2013-12-31 | F. Hoffmann-La Roche Ag | Diaminopirimidini kot modulatorji p2x3 in p2x2/3 |
| KR100881728B1 (ko) | 2007-05-04 | 2009-02-06 | 주식회사 하이닉스반도체 | 루테늄전극을 구비한 반도체소자 및 그 제조 방법 |
| EP2180894A4 (de) | 2007-07-23 | 2012-08-29 | Melior Pharmaceuticals I Inc | Verfahren zur aktivierung von irs-1 und akt |
| US8552184B2 (en) | 2008-07-03 | 2013-10-08 | Melior Pharmaceuticals I, Inc. | Compounds and methods for treating disorders related to glucose metabolism |
| US9278134B2 (en) | 2008-12-29 | 2016-03-08 | The Board Of Trustees Of The University Of Alabama | Dual functioning ionic liquids and salts thereof |
| WO2011150300A1 (en) | 2010-05-28 | 2011-12-01 | Melior Pharmaceuticals I, Inc. | Prevention of pancreatic beta cell degeneration |
| EP3110946B1 (de) | 2014-02-24 | 2021-09-01 | Energesis Pharmaceuticals Inc. | Verfahren und zusammensetzungen zur induzierung der differenzierung von vorläufern menschlicher brauner adipozyten |
| EP3609500B1 (de) * | 2017-04-10 | 2024-11-13 | Melior Pharmaceuticals I, Inc. | Behandlung von adipozyten |
-
2006
- 2006-08-22 KR KR1020087006891A patent/KR101452518B1/ko not_active Expired - Lifetime
- 2006-08-22 JP JP2008528076A patent/JP5113752B2/ja not_active Expired - Lifetime
- 2006-08-22 AU AU2006283211A patent/AU2006283211B2/en active Active
- 2006-08-22 AT AT06813647T patent/ATE533488T1/de active
- 2006-08-22 NZ NZ565955A patent/NZ565955A/en unknown
- 2006-08-22 BR BRPI0615046A patent/BRPI0615046C1/pt active IP Right Grant
- 2006-08-22 CA CA2620065A patent/CA2620065C/en not_active Expired - Lifetime
- 2006-08-22 WO PCT/US2006/032788 patent/WO2007024863A2/en not_active Ceased
- 2006-08-22 US US11/507,652 patent/US7776870B2/en not_active Expired - Lifetime
- 2006-08-22 EP EP06813647A patent/EP1924262B1/de not_active Expired - Lifetime
- 2006-08-22 KR KR1020147016962A patent/KR101577554B1/ko not_active Expired - Lifetime
-
2008
- 2008-02-19 IL IL189603A patent/IL189603A0/en active IP Right Grant
-
2010
- 2010-07-15 US US12/837,067 patent/US8343985B2/en not_active Expired - Lifetime
-
2012
- 2012-11-30 US US13/690,548 patent/US8835448B2/en not_active Expired - Lifetime
-
2014
- 2014-02-18 US US14/182,380 patent/US9216959B2/en not_active Expired - Lifetime
-
2015
- 2015-11-13 US US14/941,473 patent/US9763945B2/en not_active Expired - Lifetime
-
2017
- 2017-08-23 US US15/684,130 patent/US10251883B2/en not_active Expired - Lifetime
-
2019
- 2019-02-27 US US16/286,976 patent/US11033548B2/en not_active Expired - Lifetime
-
2021
- 2021-05-07 US US17/314,543 patent/US12070461B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL189603A0 (en) | Methods and formulations for modulating lyn kinase activity and treating related disorders | |
| CY1120922T1 (el) | Παραγωγα πυρρολιου ως φαρμακευτικοι παραγοντες | |
| EA200870019A1 (ru) | Лактамовые соединения и способы их применения | |
| DE602006004844D1 (de) | Pyrrolopyrimidine verwendbar als protein kinase inhibitoren | |
| NO20074999L (no) | Metode og preparat for behandling av perifere vaskulaere sykdommer | |
| TW200745124A (en) | Azepinoindole derivatives as pharmaceutical agents | |
| WO2007125501A3 (en) | Liquid compositions comprising phenylephrine and acetaminophen and their use for the treatment of respiratory illness | |
| NO20084256L (no) | DPP IV inhibitorformuleringer | |
| EA200801842A1 (ru) | Антитела против бета-амилоидного пептида | |
| DE602004014117D1 (de) | Thiazole zur verwendung als inhibitoren von protein-kinasen | |
| GEP20125565B (en) | Lactam compounds and their pharmaceutical use | |
| TW200510349A (en) | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor | |
| WO2007122580A3 (en) | Compositions of phenylephrine useful for treatment of respiratory illness | |
| WO2007062078A3 (en) | Thrombopoietin activity modulating compounds and methods | |
| ATE554084T1 (de) | N-hydroxyacrylamidverbindungen | |
| NO20064325L (no) | Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes | |
| NO20076405L (no) | Anvendelse av 24-nor-UDCA | |
| MX2007004765A (es) | Compuestos y metodos que modulan la actividad de la trombopoyetina. | |
| WO2006138608A3 (en) | Pharmaceutical compositions and use thereof | |
| ATE542814T1 (de) | Pyrazinkinaseinhibitoren | |
| DE602004017326D1 (de) | Tetrahydrocarbazolderivate und deren pharmazeutische verwendung | |
| TNSN08385A1 (en) | Delayed-release glucocorticoid treatment of rheumatoid disease | |
| DK1711185T3 (da) | Kombination af roscovitin-CS-682 eller dens metabolit CNDAC | |
| IL179206A0 (en) | Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same | |
| UA94213C2 (ru) | Применение полипептида одноцепочечного антитела, который подавляет активность cd40 или cd40l в приготовлении медикамента для лечения аутоиммунного заболевания |